107 related articles for article (PubMed ID: 31006280)
1. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
3. SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma.
Chen P; Wang Y; Zhu X; Huang Y; Chen J; Sun H; Wang Y; Zhao S; You Y; Wu Y; Yang T; Wei T; Duan X; Zhao T; Jia H; Ren J
Int Immunopharmacol; 2024 Mar; 130():111728. PubMed ID: 38430801
[TBL] [Abstract][Full Text] [Related]
4. Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.
Wu Z; Wang J
Discov Med; 2024 Jan; 36(180):199-208. PubMed ID: 38273760
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
[TBL] [Abstract][Full Text] [Related]
6. The action and resistance mechanisms of Lenvatinib in liver cancer.
Buttell A; Qiu W
Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.
Qiu Y; Che B; Zhang W; Zhang AV; Ge J; Du D; Li J; Peng X; Shao J
J Adv Res; 2024 May; 59():97-109. PubMed ID: 37328057
[TBL] [Abstract][Full Text] [Related]
8. [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].
Yang XR; Sun HC; Xie Q; Zhang WG; Jia WD; Zhao M; Zhao HT; Liu XF; Zhou LD; Yan S; Xu L; Wang NY; Ding Y; Zhu XD; Zhou J; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1018-1029. PubMed ID: 38016765
[TBL] [Abstract][Full Text] [Related]
9. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
Guo J; Zhao J; Xu Q; Huang D
BMC Cancer; 2023 Oct; 23(1):967. PubMed ID: 37828435
[TBL] [Abstract][Full Text] [Related]
10. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
Fan M; Chen Z; Shao W; Chen Y; Lin Z; Yi C; Li Y; Lu L; Zhou Y; Lin J
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1479-1486. PubMed ID: 37434430
[TBL] [Abstract][Full Text] [Related]
11. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
12. EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.
Lim M; Franses JW; Imperial R; Majeed U; Tsai J; Hsiehchen D
Gastroenterology; 2023 May; 164(6):1006-1008.e3. PubMed ID: 36708791
[No Abstract] [Full Text] [Related]
13. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.
Yang J; Guo Z; Song M; Pan Q; Zhao J; Huang Y; Han Y; Ouyang D; Yang C; Chen H; Di M; Tang Y; Zhu Q; Wang Q; Li Y; He J; Weng D; Xiang T; Xia J
Front Immunol; 2023; 14():1212577. PubMed ID: 37545530
[TBL] [Abstract][Full Text] [Related]
14. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway.
Zhou C; Sun BY; Zhou PY; Yang ZF; Wang ZT; Liu G; Gan W; Wang Z; Zhou J; Fan J; Yi Y; Ren N; Qiu SJ
Clin Immunol; 2023 Nov; 256():109770. PubMed ID: 37717672
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma.
Tran TT; Caulfield J; Zhang L; Schoenfeld D; Djureinovic D; Chiang VL; Oria V; Weiss SA; Olino K; Jilaveanu LB; Kluger HM
JCI Insight; 2023 Apr; 8(7):. PubMed ID: 36821392
[TBL] [Abstract][Full Text] [Related]
16. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma.
Leung CON; Yang Y; Leung RWH; So KKH; Guo HJ; Lei MML; Muliawan GK; Gao Y; Yu QQ; Yun JP; Ma S; Zhao Q; Lee TKW
Nat Commun; 2023 Oct; 14(1):6699. PubMed ID: 37872167
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected.
Porta C; Negri F; Cosmai L
Cancer; 2024 Apr; 130(8):1208-1209. PubMed ID: 38280211
[No Abstract] [Full Text] [Related]
18. Tivozanib: current status and future directions in the treatment of solid tumors.
Pal SK; Bergerot PG; Figlin RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1851-9. PubMed ID: 23013465
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor-β signaling in their molecular effects.
Wang T; Takikawa Y; Suzuki K; Kuroda H; Kakisaka K; Chiba T
Hepatol Res; 2024 Apr; ():. PubMed ID: 38666637
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Yamauchi M; Ono A; Amioka K; Fujii Y; Nakahara H; Teraoka Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Okamoto W; Miki D; Kawaoka T; Tsuge M; Imamura M; Hayes CN; Ohishi W; Kishi T; Kimura M; Suzuki N; Arihiro K; Aikata H; Chayama K; Oka S
Commun Med (Lond); 2023 Oct; 3(1):152. PubMed ID: 37880538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
